The document discusses the CRISPR-Cas9 gene editing technique and its origins, highlighting a legal dispute between the Broad Institute and the University of California over patent rights. Key figures in the dispute include Jennifer Doudna, Emmanuelle Charpentier, and Feng Zhang, with the Broad Institute holding 13 issued patents while UC has 8 pending applications. The document also outlines commercial implications and ongoing research in genetic medicine and bioengineering involving CRISPR technology.